This work summarizes the current understanding of the mechanisms providing mucociliary clearance and their disorders in respiratory diseases. It is noted that currently the understanding of the drainage function of the respiratory tract and cough formation in bronchopulmonary pathology has significantly expanded, and therefore much attention is paid to the search for opportunities to correct these parts of pathogenesis. The use of drugs improving sputum rheology and decreasing inflammatory mucosal edema are of great importance in this aspect. The article summarizes the data on the possibilities of pathogenetic correction of respiratory disorders with the emphasis on the use of expectorants and mucolytic drugs made from herbal raw materials. For many of them a sufficiently rich clinical experience has been accumulated, and modern manufacturing techniques have significantly increased their quality and safety. The mucolytic and expectorant properties of modern herbal remedies are in many cases as good as those of synthetic drugs. An important feature of herbal remedies is that they contain a combination of many components with a complex therapeutic effect, whereby the quality of herbal remedies is ensured by the most modern manufacturing control mechanisms. The paper reflects the main therapeutic effects of herbal remedies, which depend on the plant species and are determined by their content of biologically active substances: alkaloids, glycosides (including anthraglycosides, cardiac glycosides, saponins, flavonoids), phytoncides, essential oils, coumarins, tannins, resins, etc. The results of own observations on the use of herbal remedies in routine clinical practice are presented. The high adherence of patients to the use of herbal syrups and drops based on ivy extract in the therapy of cough syndrome in adults and children is shown.
13 October 2023 in Pediatria. Journal named after G.N. Speransky
In connection with the introduction of targeted therapy for cystic fibrosis (CF) into clinical practice, there is a need to study the clinical effectiveness of these drugs and to record their possible side effects in children.The aim was to present the regional experience of the Republic of Tatarstan in the use of etiopathogenetic therapy (ivacaftor + tezacaftor + elexacaftor) in 41 children diagnosed with CF.Methods. Before initiation of triple therapy, a comprehensive assessment of body functions was carried out. Monitoring of safety and effectiveness was carried out at 14 days, 1 month, 3 months, 6 months, and 12 months after from the start of therapy.Results. In the first 2 weeks from the start of therapy, 10 (27%) patients reported mild side effects in the form of increased cough, sputum, and rhinorrhea, 2 (5,4%) patients had skin rashes, and 3 (8,1%) patients had elevated blood aminotransferases. One child developed encephalopathy due to arterial hypertension several months after starting therapy.Conclusion. Monitoring of the safety of the therapy over 12 months in children with CF showed a satisfactory profile. The therapy was associated with an improvement in the body functions, nutritional status, and quality of life.
14 November 2025 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Pachydermoperiostosis is a rare genetic disease manifested by a sharp thickening and compaction of the facial skin as a result of hyperplasia of the connective tissue of the dermis and epidermis, periostosis and deformation of the distal phalanges of the fingers and nails according to the type of «drumsticks» or «watch glasses». The disease is more common in males with an onset in adolescence. One of the reasons for the development of the primary form is a mutation in the HPGD , SLCO2A1 genes, leading to a consistently elevated level of prostaglandins E2 in the blood. The secondary form of pachydermoperiostosis is characterized mainly by bone changes and pathologies of the pulmonary and cardiovascular systems.